

Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-41. (Cancelled)

42. (Currently Amended) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:

- 32
- (a) amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (b) amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (c) amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (d) a full-length polypeptide having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927;
 - (e) a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927; and
 - (f) a polypeptide having the amino acid sequence expressed by a recombinant cell comprising the cDNA plasmid contained in ATCC Deposit No. 75927, wherein said amino acid sequence is encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.

43. (Previously Amended) The isolated polypeptide of claim 42 consisting of amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID NO:2.

44. (Previously Amended) The isolated polypeptide of claim 42 consisting of amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2.

45. (Previously Amended) The isolated polypeptide of claim 42 consisting of amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID NO:2.

46. (Previously Amended) The isolated polypeptide of claim 42 consisting of a full-length polypeptide having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.

47. (Previously Amended) The isolated polypeptide of claim 42 consisting of a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.

48. (Previously Amended) The isolated polypeptide of claim 42 consisting of a polypeptide having the amino acid sequence expressed by a recombinant cell comprising the human cDNA contained in ATCC Deposit No. 75927.

49-51. (Cancelled)

52. (Previously Amended) The isolated polypeptide of claim 42 wherein said polypeptide is fused to a heterologous polypeptide.

53. (Previously Added) The isolated polypeptide of claim 52 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

54. (Previously Added) A composition comprising the polypeptide of claim 42 and a pharmaceutically acceptable carrier.

55. (Currently Amended) An isolated polypeptide encoded by a nucleic acid molecule consisting of a polynucleotide sequence selected from the group consisting of:

- 52
- (a) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of nucleotides 783 to 1304 of SEQ ID NO:1; and
 - (b) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of the open reading frame encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.

56. (Previously Amended) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (a).

57-58. (Cancelled)

59. (Previously Amended) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (b).

60-61. (Cancelled)

62. (Previously Amended) The isolated polypeptide of claim 55 wherein said polypeptide is fused to a heterologous polypeptide.

63. (Previously Added) The isolated polypeptide of claim 62 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

64. (Previously Added) A composition comprising the polypeptide of claim 55 and a pharmaceutically acceptable carrier.

65. (Previously Amended) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence consisting of at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (b) an amino acid sequence consisting of at least 30 contiguous amino acid residues encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.

32 66. (Previously Amended) The isolated polypeptide of claim 65 which consists of (a).

67-68. (Cancelled)

69. (Previously Amended) The isolated polypeptide of claim 65 which consists of (b).

70-71. (Cancelled)

72. (Previously Amended) The isolated polypeptide of claim 65 wherein said polypeptide is fused to a heterologous polypeptide.

73. (Previously Added) The isolated polypeptide of claim 72 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

32 74. (Previously Added) A composition comprising the polypeptide of claim 65 and a pharmaceutically acceptable carrier.

75-94. (Cancelled)
